{"id":"https://openalex.org/W4392703232","doi":"https://doi.org/10.1158/2159-8290.c.6546685","title":"Data from Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor\u2013Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations","display_name":"Data from Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor\u2013Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4392703232","doi":"https://doi.org/10.1158/2159-8290.c.6546685"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.c.6546685","doi":"https://doi.org/10.1158/2159-8290.c.6546685","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6546685","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2159-8290.c.6546685","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019892202","display_name":"Yelena Yuriy Janjigian","orcid":"https://orcid.org/0000-0002-5357-5858","observed_orcids":["https://orcid.org/0000-0002-5357-5858"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yelena Y. Janjigian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016904876","display_name":"Egbert Frederik Smit","orcid":"https://orcid.org/0000-0002-7329-6995","observed_orcids":["https://orcid.org/0000-0002-7329-6995"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Egbert F. Smit","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065110382","display_name":"Harry J.M. Groen","orcid":"https://orcid.org/0000-0002-2978-5265","observed_orcids":["https://orcid.org/0000-0002-2978-5265"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Harry J.M. Groen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062894702","display_name":"Leora Horn","orcid":"https://orcid.org/0000-0003-2070-2547","observed_orcids":["https://orcid.org/0000-0003-2070-2547"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leora Horn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070967174","display_name":"Scott N. Gettinger","orcid":"https://orcid.org/0000-0003-0886-6880","observed_orcids":["https://orcid.org/0000-0003-0886-6880"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Gettinger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082517668","display_name":"D. Ross Camidge","orcid":"https://orcid.org/0000-0003-3430-3213","observed_orcids":["https://orcid.org/0000-0003-3430-3213"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Ross Camidge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060033755","display_name":"Gregory J. Riely","orcid":"https://orcid.org/0000-0001-5357-4313","observed_orcids":["https://orcid.org/0000-0001-5357-4313"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory J. Riely","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086847475","display_name":"Bushi Wang","orcid":"https://orcid.org/0000-0001-8916-9416","observed_orcids":["https://orcid.org/0000-0001-8916-9416"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bushi Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100819391","display_name":"Yali Fu","orcid":"https://orcid.org/0009-0003-2934-8211","observed_orcids":["https://orcid.org/0009-0003-2934-8211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yali Fu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063821551","display_name":"Vikram K. Chand","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vikram K. Chand","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111578811","display_name":"Vincent A. Miller","orcid":"https://orcid.org/0000-0003-1667-3771","observed_orcids":["https://orcid.org/0000-0003-1667-3771"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vincent A. Miller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5062616992","display_name":"William J. Pao","orcid":"https://orcid.org/0000-0002-9888-0733","observed_orcids":["https://orcid.org/0000-0002-9888-0733"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Pao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr-mutant-lung-cancer","display_name":"EGFR-mutant lung cancer","score":0.972000002861023},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.8880000114440918},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.8920000195503235},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8479999899864197},{"id":"https://openalex.org/keywords/erlotinib-resistance","display_name":"erlotinib resistance","score":0.7739999890327454},{"id":"https://openalex.org/keywords/gefitinib-resistance","display_name":"gefitinib resistance","score":0.9940000176429749},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6679999828338623},{"id":"https://openalex.org/keywords/irreversible-egfr-inhibitors","display_name":"irreversible EGFR inhibitors","score":0.5440000295639038},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.9787307381629944},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9064866900444031},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.901573657989502},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8524680733680725},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.7822803854942322},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6875865459442139},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6492242813110352},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4277697205543518},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.38570496439933777},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3643375039100647},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36117133498191833},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.29184359312057495},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.17204779386520386}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2159-8290.c.6546685","doi":"https://doi.org/10.1158/2159-8290.c.6546685","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6546685","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/2159-8290.c.6546685.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546685.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2159-8290.c.6546685.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.c.6546685","doi":"https://doi.org/10.1158/2159-8290.c.6546685","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6546685","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2129656399","https://openalex.org/W2081583585","https://openalex.org/W2012934075","https://openalex.org/W2032712631","https://openalex.org/W2332183914","https://openalex.org/W4361960100","https://openalex.org/W2355854689","https://openalex.org/W2335505014","https://openalex.org/W1778149359","https://openalex.org/W2314031965"],"abstract_inverted_index":{"Abstract":[0],"EGFR-mutant":[1,51,133],"lung":[2,52,134],"cancers":[3,135],"responsive":[4],"to":[5,57,139,191],"reversible":[6],"EGFR":[7,16,66,196],"inhibitors":[8],"(gefitinib/erlotinib)":[9],"develop":[10],"acquired":[11,55,137,168,189],"resistance,":[12],"mediated":[13],"by":[14,209],"second-site":[15],"T790M":[17,147],"mutation":[18],"in":[19,78,118,132,165,186,219],">50%":[20],"of":[21,103,120,158,184],"cases.":[22],"Preclinically,":[23],"afatinib":[24,42,162],"(irreversible":[25],"ErbB":[26],"family":[27],"blocker)":[28],"plus":[29],"cetuximab":[30,44,164],"(anti-EGFR":[31],"monoclonal":[32],"antibody)":[33],"overcomes":[34],"T790M-mediated":[35],"resistance.":[36],"This":[37,153,215,222],"phase":[38],"Ib":[39],"study":[40],"combining":[41,161],"and":[43,54,80,99,127,145,163,170,211],"enrolled":[45],"heavily":[46],"pretreated":[47],"patients":[48,166,187],"with":[49,136,144,167,188],"advanced":[50],"cancer":[53],"resistance":[56,138,169,190],"erlotinib/gefitinib.":[58],"Patients":[59],"provided":[60],"post\u2013acquired-resistance":[61],"tumor":[62],"samples":[63],"for":[64,176,198],"profiling":[65],"mutations.":[67],"Among":[68],"126":[69],"patients,":[70],"objective":[71,105],"response":[72,106],"rate":[73],"(overall":[74],"29%)":[75],"was":[76,92,107],"comparable":[77],"T790M-positive":[79],"T790M-negative":[81],"tumors":[82,185],"(32%":[83],"vs.":[84],"25%;":[85],"P":[86],"=":[87],"0.341).":[88],"Median":[89],"progression-free":[90],"survival":[91],"4.7":[93],"months":[94,109],"(95%":[95],"confidence":[96],"interval,":[97],"4.3\u20136.4),":[98],"the":[100,156,172,177,220],"median":[101],"duration":[102],"confirmed":[104],"5.7":[108],"(range,":[110],"1.8\u201324.4).":[111],"Therapy-related":[112],"grade":[113],"3/4":[114],"adverse":[115],"events":[116],"occurred":[117],"44%/2%":[119],"patients.":[121],"Afatinib\u2013cetuximab":[122],"demonstrated":[123],"robust":[124],"clinical":[125,174],"activity":[126],"a":[128,159,181],"manageable":[129],"safety":[130],"profile":[131],"gefitinib":[140],"or":[141],"erlotinib,":[142],"both":[143],"without":[146],"mutations,":[148],"warranting":[149],"further":[150],"investigation.":[151],"Significance:":[152],"article":[154,216],"reports":[155],"results":[157],"trial":[160],"details":[171],"first":[173],"proof-of-concept":[175],"preclinical":[178],"hypothesis":[179],"that":[180],"significant":[182],"proportion":[183],"gefitinib/erlotinib":[192],"remain":[193],"dependent":[194],"on":[195],"signaling":[197],"survival.":[199],"Cancer":[200],"Discov;":[201],"4(9);":[202],"1036\u201345.":[203],"\u00a92014":[204],"AACR.":[205],"See":[206],"related":[207],"commentary":[208],"Gibbons":[210],"Byers,":[212],"p.":[213,225],"991":[214],"is":[217],"highlighted":[218],"In":[221],"Issue":[223],"feature,":[224],"973":[226]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-03-13T00:00:00"}